Siim Land Podcast #481 The Anti-Aging Pill Chinese Scientists Are Developing - Aiming for 120+ Lifespans - Yip Tszho
10 snips
Nov 29, 2025 Yip Tszho (Zico), Chief Executive of Lonvi Biosciences and a pioneer in longevity research, dives into the groundbreaking development of PCC1, a senolytic pill aimed at extending human lifespans. He explains how PCC1 selectively targets and eliminates senescent cells, possibly increasing lifespan by 9.4% in studies. The conversation explores the potential health benefits of this drug, including improved immune response and skin health. Yip also shares insights on the future of Chinese longevity science and the importance of biomarker-driven treatments.
AI Snips
Chapters
Books
Transcript
Episode notes
PCC1’s Unique Mechanism And Potency
- PCC1 is a presanidine compound purified from natural extracts that selectively targets senescent cells by pushing mitochondrial ROS over a lethal threshold.
- It works at microgram–milligram scales and contrasts with classical senolytics that require gram-level doses and broadly inhibit pro-survival pathways.
Dose Determines Senomorphic Vs Senolytic Action
- PCC1 shows dose-dependent senomorphic (lower dose) and senolytic (higher dose) effects, with different human-equivalent dose estimates.
- Estimated senolytic human dose ranges from ~120–250 mg/day while senomorphic effects may appear at ~25–30 mg/day, pending refinement.
Mice Show Rapid Hair And Tissue Improvements
- In mice, PCC1 treatment produced rapid visible changes like shinier fur and accelerated hair growth within weeks.
- The team also replicated reductions in tissue senescence markers and improved PK absorption (3×) with their formulation.
